Nomura's Bold Call: Anthem BioSciences Poised for 18% Surge? See the Target Price!

BROKERAGE-REPORTS
Whalesbook Logo
AuthorAditi Singh|Published at:
Nomura's Bold Call: Anthem BioSciences Poised for 18% Surge? See the Target Price!
Overview

Global brokerage Nomura has initiated coverage on Anthem BioSciences Ltd. with a 'Buy' rating and a ₹740 price target, signaling a potential 18% upside. The firm is optimistic about the company's CRDMO capabilities, projecting strong sales and earnings growth driven by new launches and capacity expansion.

Nomura has initiated coverage on Anthem BioSciences Ltd. with a 'Buy' recommendation and a price target of ₹740 per share. This development suggests a potential upside of approximately 18% from its current trading levels, drawing significant investor attention.

Nomura's Positive Stance on CRDMO Growth

  • The global brokerage firm views Anthem BioSciences as strategically positioned to capitalize on the expanding Contract Research, Development, and Manufacturing Organisation (CRDMO) market opportunity.
  • Nomura's analysis highlights the company's potential for substantial financial growth, projecting sales to increase by 14%, 18%, and 22% over fiscal years 2026, 2027, and 2028, respectively.
  • Earnings are expected to see even more robust growth, with forecasts of 27%, 21%, and 26% for the same periods.

Factors Driving Future Performance

  • While near-term revenue growth might see a slight moderation from a high base, Nomura anticipates a re-acceleration in FY27F and FY28F.
  • This accelerated growth is expected to be driven by sustained demand for its existing product portfolio, the successful introduction of new products, and ongoing capacity expansions.
  • The brokerage's positive medium-term outlook is underpinned by the sustained end-market growth of key molecules, the pipeline of fresh product launches, and the continuous expansion of its manufacturing capabilities.

About Anthem BioSciences Ltd.

  • Established in 2006, Anthem BioSciences operates as a comprehensive CRDMO.
  • It provides end-to-end solutions for pharmaceutical and biotechnology firms, encompassing the entire drug development lifecycle, from early-stage research through to commercial manufacturing.
  • The company's integrated operational model is designed to simplify complex processes and mitigate compliance challenges for its clients, offering a seamless service experience.

Recent Stock Performance and Market Context

  • Anthem BioSciences shares concluded Thursday's trading session 1.20% lower, closing at ₹625 per share.
  • The stock is currently trading at a premium of approximately 10% above its Initial Public Offering (IPO) price of ₹570.
  • However, it remains significantly below its post-listing high of ₹873.50, trading about 28% lower than its peak.
  • Over the past month, the stock has experienced a decline of 13%.

Importance of the Event

  • The initiation of coverage by a prominent global brokerage like Nomura often serves as a catalyst for increased investor interest and can significantly influence market sentiment towards a stock.
  • A 'Buy' rating coupled with a specific, attractive price target provides a clear investment thesis and a benchmark for potential future stock performance.
  • Anthem BioSciences' strong positioning in the CRDMO sector, a critical and growing segment of the pharmaceutical industry, makes this analyst coverage particularly relevant for tracking industry growth.

Impact

  • This news is likely to stimulate positive investor sentiment and could lead to increased buying activity in Anthem BioSciences shares, potentially pushing the stock price towards Nomura's target of ₹740.
  • Such analyst coverage might also encourage other institutional investors and analysts to conduct their own evaluations, potentially leading to broader positive attention and price appreciation.
  • The sector itself could see renewed interest, benefiting other companies operating within the CRDMO space.
  • Impact Rating: 8

Difficult Terms Explained

  • CRDMO: Contract Research, Development, and Manufacturing Organisation. These are specialized firms that provide outsourced services to the pharmaceutical and biotechnology industries, assisting in drug discovery, clinical trials, development, and large-scale manufacturing.
  • FY26F, FY27F, FY28F: These notations refer to forecasted fiscal years 2026, 2027, and 2028, respectively. The 'F' signifies that these figures are projections or forecasts made by analysts.
  • IPO: Initial Public Offering. This is the process by which a private company first sells its shares to the public, becoming a publicly traded entity.
  • Post-listing high: The highest price achieved by a company's stock on the stock exchange since it was first listed.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.